All Clinical Trials
Official Title A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
Phase Phase III
ClinicalTrials.gov NCT00035789
Treatments
Entecavir
, Entecavir
Tradename:BaracludeOther Names:ETVClass:Oral Antivirals (Nucleos(t)ide Analogues)Lamivudine
Lamivudine
Tradename:Epivir HBVOther Names:3TCClass:Oral Antivirals (Nucleos(t)ide Analogues)Funding
IndustryBristol-Meyers Squibb
References
- Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-20.
Official Title A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
Phase Phase III
ClinicalTrials.gov NCT00035633
Treatments
Entecavir
, Entecavir
Tradename:BaracludeOther Names:ETVClass:Oral Antivirals (Nucleos(t)ide Analogues)Lamivudine
Lamivudine
Tradename:Epivir HBVOther Names:3TCClass:Oral Antivirals (Nucleos(t)ide Analogues)Funding
IndustryBristol-Meyers Squibb
References
- Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
- Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437-44.